Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial
MCT-CX is a plausible treatment option in far advanced breast cancer, with almost half of trial participants responding to treatment without QoL impairments.
Authors
- Leif Klint
- Karolina Larsson (ORCID: https://orcid.org/0000-0003-2347-3591)
- Jamila Adra (ORCID: https://orcid.org/0000-0001-6361-661X)
- Barbro Linderholm (ORCID: https://orcid.org/0000-0003-1531-630X)
Institutions
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- The Breast
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.breast.2024.103795
- Citations
- 4
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Anna-Lisa och Bror Björnssons Stiftelse
- Sahlgrenska Universitetssjukhuset
- Göteborgs Universitet
- Sahlgrenska Akademin